
|Articles|June 10, 2015 (Updated: April 18, 2020)
- Precision Medicine
- Volume 2
- Issue 1
Significance of the NCI Molecular Analysis for Therapy Choice Program
Author(s)Jonathan C. Trent, MD, PhD
Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).
Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).
<<<
Articles in this issue
over 10 years ago
Nivolumab and Future Biomarkers in NSCLCover 10 years ago
Clinical Validation and Utility of a Liquid Biopsy in NSCLCRelated Content
Advertisement



Safety and Antitumor Activity Revealed for T-Cell Engager XmAb819 in RCC
Published: | Updated:

Sarcomatoid Features May Be a Biomarker in Chromophobe RCC
Published: | Updated:

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma
Published: | Updated:



























